Its activation mitigates clinical symptoms, and Drd2 knockout (Drd2KO) mice develop severe symptoms of RA; D2R antagonists induce the accumulation of IL-17+ and IL-6+ T cells in synovial fluid, exacerbating the inflammatory process. This evidence concerns the gene IL17A and rheumatoid arthritis.